Abstract 606P
Background
Cutaneous melanoma is considered a rare but lethal cancer among Asians. Prognosis is generally worse with high rates of recurrences and mortality. Clinical presentations show striking differences with cutaneous melanoma among Caucasian. Acral lentiginous and nodular melanoma are the most common subtypes among Asian. Patterns of mutations and molecular alterations and the association with prognosis are not yet known among melanoma patients in Indonesia. This study aims to analyze association between BRAF dan NRAS mutations with overall survival of melanoma patients in Indonesia.
Methods
DNA from formalin-fixed paraffin embedded tissues from melanoma patients were extracted. PCR and pyrosequencing were performed to detect mutations in the BRAF dan NRAS genes.
Results
Of 51 melanoma patients, 44 patients (86.3%) were diagnosed with Breslow thickness more than 4 mm (T4). In the primary cutaneous melanoma lesions, 33 (67%) patients had ulceration, 47 patients (92.2%) had diameter more than 6 mm, and 30 patient (58.2%) had positive regional lymph nodes. In this study, BRAF mutations were found in 26 patients (56%) and NRAS mutations were found in 5 patients (9.8%). BRAF mutations were found in older age than 65 years although the difference was not significant (OR 2.205, 95%CI: 0.558-8.717, P=0.259). BRAF mutations were associated with significantly lower overall survivals compared to wild-type (median survivals were 18 vs 34 months, P=0.042). Although patients with NRAS mutations had shorter survival, the difference was not statistically significant (P=0.120). Patients with BRAF or NRAS were associated with significant lower overall survivals compared to those with wild-type (Median survivals were 19 vs 35 months, P=0.044).
Conclusions
BRAF and / or NRAS mutations were associated with shorter survival among cutaneous melanomas in Indonesia with predominant subtypes of acral lentiginous and nodular melanomas. Larger study from Asian population is required to extend our finding to establish a prognostic marker as well as a potential targeted treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gadjah Mada University.
Funding
Gadjah Mada University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract